The immunotherapeutic vaccine candidate targets a toxic peptide called amyloid beta that is believed to damage the brain and trigger Alzheimer’s.
The FDA’s fast track program is designed to expedite the development and review of drugs intended to treat serious or life-threatening conditions.
Vaxxinity is slated to launch a phase 2B trial for the vaccine later this year, the company said in a May 2 press release.
Learn more here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
